doi:10.48130/targetome-0026-0028

[1]

Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, et al. 2021. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: state-of-the-arts and future directions. Medicinal Research Reviews 41:1427−1473

doi: 10.1002/med.21764

[2]

Naqvi S, Panghal A, Flora SJS. 2020. Nanotechnology: a promising approach for delivery of neuroprotective drugs. Frontiers in Neuroscience 14:494

doi: 10.3389/fnins.2020.00494

[3]

Zhao L, Zhao J, Zhong K, Tong A, Jia D. 2022. Targeted protein degradation: mechanisms, strategies and application. Signal Transduction and Targeted Therapy 7:113

doi: 10.1038/s41392-022-00966-4

[4]

Guan X, Yu XY, Zhang L. 2026. A breakthrough in NSCLC therapy: targeted protein degradation of CD26 via PROTACs. eBioMedicine 123:106082

doi: 10.1016/j.ebiom.2025.106082

[5]

Wang X, Chen S, Xia X, Du Y, Wei Y, et al. 2025. Lysosome-targeting protein degradation through endocytosis pathway triggered by polyvalent nano-chimera for AD therapy. Advanced Materials 37:2411061

doi: 10.1002/adma.202411061

[6]

Xiao Y, He Z, Li W, Chen D, Niu X, et al. 2025. A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy. Nature Communications 16:1388

doi: 10.1038/s41467-025-56648-6

[7]

Bae TH, Sung KW, Pham TM, Najy AJ, Zamiri A, et al. 2025. An autophagy-targeting chimera induces degradation of androgen receptor mutants and AR-v7 in castration-resistant prostate cancer. Cancer Research 85:342−359

doi: 10.1158/0008-5472.CAN-24-0591

[8]

Song Z, Gao Y, Zou X, Wang Z, Zhang S, et al. 2026. Inducing potent ferroptosis in cancer cells by manipulation of ferritinophagy with a ferritin-targeted ATTEC. Journal of Controlled Release 389:114450

doi: 10.1016/j.jconrel.2025.114450

[9]

Duan Y, Cai MY, Xu J, Hu Q. 2025. Rational design of the linkers in targeting chimeras. Chemical Science 16:17595−17610

doi: 10.1039/d5sc04859a

[10]

Chen Y, Tandon I, Heelan W, Wang Y, Tang W, et al. 2022. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation. Chemical Society Reviews 51:5330−5350

doi: 10.1039/d1cs00762a

[11]

Liang X, Ren H, Han F, Liang R, Zhao J, et al. 2024. The new direction of drug development: degradation of undruggable targets through targeting chimera technology. Medicinal Research Reviews 44:632−685

doi: 10.1002/med.21992

[12]

Pike A, Williamson B, Harlfinger S, Martin S, McGinnity DF. 2020. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discovery Today 25:1793−1800

doi: 10.1016/j.drudis.2020.07.013

[13]

Drummond ML, Williams CI. 2019. In silico modeling of PROTAC-mediated ternary complexes: validation and application. Journal of Chemical Information and Modeling 59:1634−1644

doi: 10.1021/acs.jcim.8b00872

[14]

Kong NR, Jones LH. 2023. Clinical translation of targeted protein degraders. Clinical Pharmacology & Therapeutics 114:558−568

doi: 10.1002/cpt.2985

[15]

Wang C, Zhang Y, Wang J, Xing D. 2022. VHL-based PROTACs as potential therapeutic agents: recent progress and perspectives. European Journal of Medicinal Chemistry 227:113906

doi: 10.1016/j.ejmech.2021.113906

[16]

Ji CH, Lee MJ, Kim HY, Heo AJ, Park DY, et al. 2022. Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera). Autophagy 18:2259−2262

doi: 10.1080/15548627.2022.2091338

[17]

Zou Y, Ma D, Wang Y. 2019. The PROTAC technology in drug development. Cell Biochemistry and Function 37:21−30

doi: 10.1002/cbf.3369

[18]

An S, Fu L. 2018. Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs. eBioMedicine 36:553−562

doi: 10.1016/j.ebiom.2018.09.005

[19]

Cromm PM, Crews CM. 2017. Targeted protein degradation: from chemical biology to drug discovery. Cell Chemical Biology 24:1181−1190

doi: 10.1016/j.chembiol.2017.05.024

[20]

Jin J, Wu Y, Chen J, Shen Y, Zhang L, et al. 2020. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. Theranostics 10:10141−10153

doi: 10.7150/thno.46985

[21]

Lazo JS, Sharlow ER. 2016. Drugging undruggable molecular cancer targets. Annual Review of Pharmacology and Toxicology 56:23−40

doi: 10.1146/annurev-pharmtox-010715-103440

[22]

Luo H, Tian Y, Abdullah R, Zhang B, Ma Y, et al. 2025. Advancing design strategy of PROTACs for cancer therapy. MedComm 6:e70258

doi: 10.1002/mco2.70258

[23]

Keefe AD, Pai S, Ellington A. 2010. Aptamers as therapeutics. Nature Reviews Drug Discovery 9:537−550

doi: 10.1038/nrd3141

[24]

Cao C, Li A, Xu C, Wu B, Yao L, et al. 2025. Engineering artificial non-coding RNAs for targeted protein degradation. Nature Chemical Biology 21:393−401

doi: 10.1038/s41589-024-01719-w

[25]

Schaefer D, Cheng X. 2023. Recent advances in covalent drug discovery. Pharmaceuticals 16:663

doi: 10.3390/ph16050663

[26]

Grimster NP. 2021. Covalent PROTACs: the best of both worlds? RSC Medicinal Chemistry 12:1452−1458

doi: 10.1039/d1md00191d

[27]

Ebadi P, Stratton CM, Olsen SK. 2025. E3 ubiquitin ligases in signaling, disease, and therapeutics. Trends in Biochemical Sciences 50:960−976

doi: 10.1016/j.tibs.2025.07.009

[28]

Wang Y, Jiang X, Feng F, Liu W, Sun H. 2020. Degradation of proteins by PROTACs and other strategies. Acta Pharmaceutica Sinica B 10:207−238

doi: 10.1016/j.apsb.2019.08.001

[29]

Sobierajski T, Małolepsza J, Pichlak M, Gendaszewska-Darmach E, Błażewska KM. 2024. The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation. Drug Discovery Today 29:104032

doi: 10.1016/j.drudis.2024.104032

[30]

Lee J, Lee Y, Jung YM, Park JH, Yoo HS, et al. 2022. Discovery of E3 ligase ligands for target protein degradation. Molecules 27:6515

doi: 10.3390/molecules27196515

[31]

Kannt A, Đikić I. 2021. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation. Cell Chemical Biology 28:1014−1031

doi: 10.1016/j.chembiol.2021.04.007

[32]

Ahn G, Riley NM, Kamber RA, Wisnovsky S, Moncayo von Hase S, et al. 2023. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. Science 382:eadf6249

doi: 10.1126/science.adf6249

[33]

Teng F, Liu J, Cui T, Tan X, Liu K, et al. 2026. Efficient amyloid-β degradation in Alzheimer's disease using SPYTACs. Cell 189:1−19

doi: 10.1016/j.cell.2026.01.034

[34]

Lu RHH, Krishna J, Alp Y, Thayumanavan S. 2026. Polymeric lysosome-targeting chimeras (PolyTACs): extracellular targeted protein degradation without co-opting lysosome-targeting receptors. Journal of the American Chemical Society 148:1259−1270

doi: 10.1021/jacs.5c17519

[35]

Webb T, Craigon C, Ciulli A. 2022. Targeting epigenetic modulators using PROTAC degraders: current status and future perspective. Bioorganic & Medicinal Chemistry Letters 63:128653

doi: 10.1016/j.bmcl.2022.128653

[36]

Hu Z, Chen PH, Li W, Douglas T, Hines J, et al. 2023. Targeted dephosphorylation of tau by phosphorylation targeting chimeras (PhosTACs) as a therapeutic modality. Journal of the American Chemical Society 145:4045−4055

doi: 10.1021/jacs.2c11706

[37]

Zheng J, Tian N, Liu F, Zhang Y, Su J, et al. 2021. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies. Signal Transduction and Targeted Therapy 6:269

doi: 10.1038/s41392-021-00669-2

[38]

Tong Y, Zhang P, Yang X, Liu X, Zhang J, et al. 2024. Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera. Proceedings of the National Academy of Sciences of the United States of America 121:e2306682120

doi: 10.1073/pnas.2306682120

[39]

Xia LW, Ba MY, Liu W, Cheng W, Hu CP, et al. 2019. Triazol: a privileged scaffold for proteolysis targeting chimeras. Future Medicinal Chemistry 11:2919−2973

doi: 10.4155/fmc-2019-0159

[40]

Ayinde OR, Sharpe C, Stahl E, Tokarski RJ II, Lerma JR, et al. 2023. Examination of the impact of triazole position within linkers on solubility and lipophilicity of a CDK9 degrader series. ACS Medicinal Chemistry Letters 14:936−942

doi: 10.1021/acsmedchemlett.3c00082

[41]

Song C, Jiao Z, Hou Z, Wang R, Lian C, et al. 2023. Selective protein of interest degradation through the split-and-mix liposome proteolysis targeting chimera approach. Journal of the American Chemical Society 145:21860−21870

doi: 10.1021/jacs.3c05948

[42]

Liu J, Chen H, Ma L, He Z, Wang D, et al. 2020. Light-induced control of protein destruction by opto-PROTAC. Science Advances 6:eaay5154

doi: 10.1126/sciadv.aay5154

[43]

Dong Y, Ma T, Xu T, Feng Z, Li Y, et al. 2024. Characteristic roadmap of linker governs the rational design of PROTACs. Acta Pharmaceutica Sinica B 14:4266−4295

doi: 10.1016/j.apsb.2024.04.007

[44]

Zhong G, Chang X, Xie W, Zhou X. 2024. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduction and Targeted Therapy 9:308

doi: 10.1038/s41392-024-02004-x

[45]

Haridas V, Dutta S, Munjal A, Singh S. 2024. Inhibitors to degraders: changing paradigm in drug discovery. iScience 27:109574

doi: 10.1016/j.isci.2024.109574

[46]

Ruschak AM, Religa TL, Breuer S, Witt S, Kay LE. 2010. The proteasome antechamber maintains substrates in an unfolded state. Nature 467:868−871

doi: 10.1038/nature09444

[47]

Al Mamun A, Uddin MS, Kabir MT, Khanum S, Sarwar MS, et al. 2020. Exploring the promise of targeting ubiquitin-proteasome system to combat Alzheimer's disease. Neurotoxicity Research 38:8−17

doi: 10.1007/s12640-020-00185-1

[48]

Lee JH, Yang DS, Goulbourne CN, Im E, Stavrides P, et al. 2022. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nature Neuroscience 25:688−701

doi: 10.1038/s41593-022-01084-8

[49]

Ahn G, Banik SM, Miller CL, Riley NM, Cochran JR, et al. 2021. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nature Chemical Biology 17:937−946

doi: 10.1038/s41589-021-00770-1

[50]

Liu H, Dai C, Fan Y, Guo B, Ren K, et al. 2017. From autophagy to mitophagy: the roles of P62 in neurodegenerative diseases. Journal of Bioenergetics and Biomembranes 49:413−422

doi: 10.1007/s10863-017-9727-7

[51]

Nematullah M, Hoda MN, Khan F. 2018. Protein phosphatase 2A: a double-faced phosphatase of cellular system and its role in neurodegenerative disorders. Molecular Neurobiology 55:1750−1761

doi: 10.1007/s12035-017-0444-3

[52]

Fan G, Chen S, Zhang Q, Yu N, Shen Z, et al. 2025. Proteolysis-targeting chimera (PROTAC): current applications and future directions. MedComm 6:e70401

doi: 10.1002/mco2.70401

[53]

Chi KN, McKay RR, Sandhu S, Arranz Arija JA, Barthelemy P, et al. 2025. A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator's choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge). Journal of Clinical Oncology 43:TPS5119

doi: 10.1200/JCO.2025.43.16_suppl.TPS5119

[54]

Rathkopf D, Patel MR, Choudhury AD, Rasco D, Lakhani NJ, et al. 2024. 1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology 35:S962−S963

doi: 10.1016/j.annonc.2024.08.1678

[55]

Petrylak DP, McKean M, Lang JM, Gao X, Dreicer R, et al. 2024. ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. Journal of Clinical Oncology 42:5011

doi: 10.1200/JCO.2024.42.16_suppl.5011

[56]

Agarwal S, McDonald AA, Campbell V, Chen D, Davis J, et al. 2025. Pharmacokinetics and pharmacodynamics of KT-474, a novel selective interleukin-1 receptor–associated Kinase 4 (IRAK4) degrader, in healthy adults. Clinical and Translational Science 18:e70181

doi: 10.1111/cts.70181

[57]

Chen L, Luo R, Ma L, Xu Y, Cao J, et al. 2024. Discovery of LC-MI-3: a potent and orally bioavailable degrader of interleukin-1 receptor-associated kinase 4 for the treatment of inflammatory diseases. Journal of Medicinal Chemistry 67:8060−8076

doi: 10.1021/acs.jmedchem.4c00181

[58]

Groocock L, Deb G, Zhu J, Gamez J, Castiglioni P, et al. 2024. BMS-986458 a potential first-in-class, highly selective, potent and well tolerated BCL6 ligand directed degrader (LDD) demonstrates multi-modal anti-tumor efficacy for the treatment of B-cell non-Hodgkin's lymphoma. Blood 144:957

doi: 10.1182/blood-2024-210951

[59]

Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, et al. 2024. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science 383:eadi5798

doi: 10.1126/science.adi5798

[60]

Rallabandi NC, Panpatil D, Gahtory D, Navik U, Kumar R. 2025. EGFR molecular degraders: preclinical successes and the road ahead. Future Medicinal Chemistry 17:633−636

doi: 10.1080/17568919.2025.2463871

[61]

Ren J, Wang J, Xu S, Liu J, Zhang Y, et al. 2025. Abstract 400: Preclinical development of TQB3019: a potent and selective oral BTK degrader leveraging the OAPD® platform to overcome acquired resistance mutations. Cancer Research 85:400

doi: 10.1158/1538-7445.AM2025-400

[62]

Yap TA, Gutierrez M, Iams WT, Moreno V, Hernandez Guerrero T, et al. 2025. A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation. Journal of Clinical Oncology 43:TPS8667

doi: 10.1200/JCO.2025.43.16_suppl.TPS8667

[63]

Sen S, Hezel AF, Kasi A, Lakhani NJ, Spira AI, et al. 2025. Trial in progress: phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutations. Journal of Clinical Oncology 43:TPS3178

doi: 10.1200/JCO.2025.43.16_suppl.TPS3178

[64]

Nagashima T, Yoshinari T, Nishizono Y, Tasaki M, Inamura K, et al. 2023. Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models. Cancer Research 83:5735

doi: 10.1158/1538-7445.AM2023-5735

[65]

Feng X, Wang Y, Long T, Bai L, Yang X, et al. 2023. P1239: Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi). HemaSphere 7:e368855c

doi: 10.1097/01.HS9.0000971848.36885.5c

[66]

Salvaris RT, Brennan J, Lewis KL. 2025. BTK is the target that keeps on giving: a review of BTK-degrader drug development, clinical data, and future directions in CLL. Cancers 17:557

doi: 10.3390/cancers17030557

[67]

Guo Y, Cheng R, Wang Y, Gonzalez ME, Zhang H, et al. 2024. Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic. eBioMedicine 100:104972

doi: 10.1016/j.ebiom.2024.104972

[68]

Chi KN, McKay RR, Sandhu S, Arranz JA, Barthélémy P, et al. 2025. rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC. Future Oncology 21:1771−1777

doi: 10.1080/14796694.2025.2502318

[69]

Yamada K, Kihara T, Shinsato K, Yasui H, Shino M, et al. 2025. Nasal powder formulation employing microenvironmental pH-modifier for rapid absorption of mirtazapine. Pharmaceutical Science Advances 3:100068

doi: 10.1016/j.pscia.2025.100068

[70]

Lu D, Sun Y, Luan Y, He W. 2024. Rational design of siRNA-based delivery systems for effective treatment of brain diseases. Pharmaceutical Science Advances 2:100041

doi: 10.1016/j.pscia.2024.100041

[71]

Xu J, Ma C, Hua M, Li J, Xiang Z, et al. 2022. CNS and CNS diseases in relation to their immune system. Frontiers in Immunology 13:1063928

doi: 10.3389/fimmu.2022.1063928

[72]

Meyer AH, Feldsien TM, Mezler M, Untucht C, Venugopalan R, et al. 2023. Novel developments to enable treatment of CNS diseases with targeted drug delivery. Pharmaceutics 15:1100

doi: 10.3390/pharmaceutics15041100

[73]

Ma K, Han XX, Yang XM, Zhou SL. 2021. Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system. Neural Regeneration Research 16:1944−1949

doi: 10.4103/1673-5374.308075

[74]

Lin J, Jin J, Shen Y, Zhang L, Gong G, et al. 2021. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics 11:8337−8349

doi: 10.7150/thno.62686

[75]

Assaad F, Salma A, Mrad M. 2025. Epidemiological profile of adult primary brain tumors. Surgical Neurology International 16:310

doi: 10.25259/sni_280_2025

[76]

Yang T, Hu Y, Miao J, Chen J, Liu J, et al. 2022. A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization. Acta Pharmaceutica Sinica B 12:2658−2671

doi: 10.1016/j.apsb.2022.02.009

[77]

Yuan Z, Guo M, Zhang Y, Deng Y, Sun B, et al. 2025. MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell. Cell Death Discovery 11:109

doi: 10.1038/s41420-025-02392-1

[78]

Yin J, Kim SS, Choi E, Oh YT, Lin W, et al. 2020. ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. Nature Communications 11:2978

doi: 10.1038/s41467-020-16789-2

[79]

Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, et al. 2021. Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma. Clinical Cancer Research 27:6514−6528

doi: 10.1158/1078-0432.Ccr-21-1392

[80]

Bollu LR, Bommi PV, Monsen PJ, Zhai L, Lauing KL, et al. 2022. Identification and characterization of a novel indoleamine 2,3-dioxygenase 1 protein degrader for glioblastoma. Journal of Medicinal Chemistry 65:15642−15662

doi: 10.1021/acs.jmedchem.2c00771

[81]

Fang Y, Wang J, Zhao M, Zheng Q, Ren C, et al. 2022. Progress and challenges in targeted protein degradation for neurodegenerative disease therapy. Journal of Medicinal Chemistry 65:11454−11477

doi: 10.1021/acs.jmedchem.2c00844

[82]

Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. 2023. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nature Reviews Neurology 19:715−736

doi: 10.1038/s41582-023-00883-2

[83]

Zhang ZY, Harischandra DS, Wang R, Ghaisas S, Zhao JY, et al. 2023. TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease. Science 381:eadd6696

doi: 10.1126/science.add6696

[84]

Wang W, Zhou Q, Jiang T, Li S, Ye J, et al. 2021. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models. Theranostics 11:5279−5295

doi: 10.7150/thno.55680

[85]

Qu L, Li S, Ji L, Luo S, Ding M, et al. 2021. Discovery of PT-65 as a highly potent and selective proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease. European Journal of Medicinal Chemistry 226:113889

doi: 10.1016/j.ejmech.2021.113889

[86]

Schönfeld J, Brunst S, Ciomirtan L, Willmer L, Chromik MA, et al. 2025. Structure-based design of PROTACS for the degradation of soluble epoxide hydrolase. Journal of Medicinal Chemistry 68:13728−13749

doi: 10.1021/acs.jmedchem.5c00552

[87]

Lee J, Sung KW, Bae EJ, Yoon D, Kim D, et al. 2023. Targeted degradation of α-synuclein aggregates in Parkinson's disease using the AUTOTAC technology. Molecular Neurodegeneration 18:41

doi: 10.1186/s13024-023-00630-7

[88]

Xu Z, Huang X, Zhu Z, Liang F, Hu H, et al. 2025. Elevated blood microplastics and their potential association with Parkinson's disease. Journal of Hazardous Materials 500:140431

doi: 10.1016/j.jhazmat.2025.140431

[89]

Pedrini M, Iannielli A, Meneghelli L, Passarella D, Broccoli V, et al. 2023. Synthesis and preliminary characterization of putative Anle138b-centered PROTACs against α-synuclein aggregation. Pharmaceutics 15:1467

doi: 10.3390/pharmaceutics15051467

[90]

Lind-Holm Mogensen F, Scafidi A, Poli A, Michelucci A. 2023. PARK7/DJ-1 in microglia: implications in Parkinson's disease and relevance as a therapeutic target. Journal of Neuroinflammation 20:95

doi: 10.1186/s12974-023-02776-z

[91]

Jia Y, Oyken M, Kim RQ, Tjokrodirijo RTN, de Ru AH, et al. 2024. Development of inhibitors, probes, and PROTAC provides a complete toolbox to study PARK7 in the living cell. Journal of Medicinal Chemistry 67:7935−7953

doi: 10.1021/acs.jmedchem.3c02410

[92]

Ge R, Chen M, Wu S, Huang S, Zhou P, et al. 2025. DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases. Nature Communications 16:4683

doi: 10.1038/s41467-025-60039-2

[93]

Mackenzie IR, Rademakers R, Neumann M. 2010. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. The Lancet Neurology 9:995−1007

doi: 10.1016/s1474-4422(10)70195-2

[94]

Rezvykh AP, Ustyugov AA, Chaprov KD, Teterina EV, Nebogatikov VO, et al. 2023. Cytoplasmic aggregation of mutant FUS causes multistep RNA splicing perturbations in the course of motor neuron pathology. Nucleic Acids Research 51:5810−5830

doi: 10.1093/nar/gkad319

[95]

Xu X, Shen D, Gao Y, Zhou Q, Ni Y, et al. 2021. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? Translational Neurodegeneration 10:29

doi: 10.1186/s40035-021-00250-5

[96]

Tseng YL, Lu PC, Lee CC, He RY, Huang YA, et al. 2023. Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera. Journal of Biomedical Science 30:27

doi: 10.1186/s12929-023-00921-7

[97]

Xiao F, Tan X, He A, Zhou Y, Xu K, et al. 2026. Metabolites released from apoptotic cells in central nervous system orchestrates the pathological process of Alzheimer disease through improving autophagy. Autophagy 22:779−794

doi: 10.1080/15548627.2026.2615978

[98]

Wen J, Zhao M, Xiao Y, Li S, Hu W. 2024. OATP1A2 mediates Aβ1-42 transport and may be a novel target for the treatment of Alzheimer's disease. Frontiers in Pharmacology 15:1443789

doi: 10.3389/fphar.2024.1443789

[99]

Silva-Llanes I, Rodríguez-López S, González-Naranjo P, del Sastre E, López MG, et al. 2025. Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model. Brain, Behavior, and Immunity 127:251−268

doi: 10.1016/j.bbi.2025.03.008

[100]

Fang X, Jin H, Wang J, Zhang R, Li B. 2025. Gating mechanism of the two-pore-domain potassium channel THIK1. Nature Structural & Molecular Biology 32:1175−1182

doi: 10.1038/s41594-025-01542-4

[101]

Tan S, Wang D, Fu Y, Zheng H, Liu Y, et al. 2023. Targeted clearance of mitochondria by an autophagy-tethering compound (ATTEC) and its potential therapeutic effects. Science Bulletin 68:3013−3026

doi: 10.1016/j.scib.2023.10.021

[102]

Jin Y, Han G, Gao Y, Cheng H, Sun C, et al. 2025. Serum-tolerant polymeric complex for stem-cell transfection and neural differentiation. Nature Communications 16:2022

doi: 10.1038/s41467-025-57278-8

[103]

Bu S, Ji J, Yang M, Sun J, Zhang J, et al. 2024. Chemical composition and neuroprotective activity of hemp seed aqueous extract and their chemotaxonomic significance. Pharmaceutical Science Advances 2:100051

doi: 10.1016/j.pscia.2024.100051

[104]

Pan M, Fu Z, Hou H, Yang C, Li J. 2025. Proteolysis-targeting chimera (PROTAC): a revolutionary tool for chemical biology research. Small Methods 9:2500402

doi: 10.1002/smtd.202500402

[105]

Hu Z, Crews CM. 2022. Recent developments in PROTAC-mediated protein degradation: from bench to clinic. ChemBioChem 23:e202100270

doi: 10.1002/cbic.202100270

[106]

Yao Y, Xu Z, Ding H, Yang S, Chen B, et al. 2025. Carrier-free nanoparticles − new strategy of improving druggability of natural products. Journal of Nanobiotechnology 23:108

doi: 10.1186/s12951-025-03146-y

[107]

Jeong J, Cho H, Moon Y, Shim N, Kim J, et al. 2026. Effective degradation of wild-type and mutant EGFR using self-assembling peptide-derived PROTAC nanoparticles (NanoTACs) for cancer therapy. Advanced Materials 38:e16974

doi: 10.1002/adma.202516974

[108]

Jang Y, Choi J, Park B, Park JY, Lee JH, et al. 2025. Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy. Acta Pharmaceutica Sinica B 15:4886−4899

doi: 10.1016/j.apsb.2025.06.028

[109]

Jin T, Li D, Yang T, Liu F, Kong J, et al. 2019. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival. Oncology Reports 42:717−725

doi: 10.3892/or.2019.7180

[110]

Wiede F, Lu KH, Du X, Zeissig MN, Xu R, et al. 2022. PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discovery 12:752−773

doi: 10.1158/2159-8290.Cd-21-0694

[111]

Digiovanni S, Lorenzati M, Bianciotto OT, Godel M, Fontana S, et al. 2024. Blood-brain barrier permeability increases with the differentiation of glioblastoma cells in vitro. Fluids and Barriers of the CNS 21:89

doi: 10.1186/s12987-024-00590-0

[112]

Cuevas E, Rosas-Hernandez H, Burks SM, Ramirez-Lee MA, Guzman A, et al. 2019. Amyloid Beta 25–35 induces blood-brain barrier disruption in vitro. Metabolic Brain Disease 34:1365−1374

doi: 10.1007/s11011-019-00447-8

[113]

Zhang YL, Wang J, Zhang ZN, Su Q, Guo JH. 2022. The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer's disease. Neural Regeneration Research 17:2355−2363

doi: 10.4103/1673-5374.335829

[114]

Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. 2019. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews Neurology 15:501−518

doi: 10.1038/s41582-019-0228-7

[115]

Yu W, Xuan C, Liu B, Zhou L, Yin N, et al. 2023. Carrier-free programmed spherical nucleic acid for effective ischemic stroke therapy via self-delivery antisense oligonucleotide. Nano Research 16:735−745

doi: 10.1007/s12274-022-4402-7

[116]

Yu W, Che C, Yang Y, Zhao Y, Liu J, et al. 2025. Bioactive self-assembled nanoregulator enhances hematoma resolution and inhibits neuroinflammation in the treatment of intracerebral hemorrhage. Advanced Science 12:e2408647

doi: 10.1002/advs.202408647

[117]

Ma F, Yang L, Sun Z, Chen J, Rui X, et al. 2020. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. Science Advances 6:eabb4429

doi: 10.1126/sciadv.abb4429

[118]

Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal DR, et al. 2025. Neuroinflammation in Alzheimer disease. Nature Reviews Immunology 25:321−352

doi: 10.1038/s41577-024-01104-7

[119]

Gong B, Zhang W, Cong W, Gu Y, Ji W, et al. 2024. Systemic administration of neurotransmitter-derived lipidoids-PROTACs-DNA nanocomplex promotes tau clearance and cognitive recovery for Alzheimer's disease therapy. Advanced Healthcare Materials 13:e2400149

doi: 10.1002/adhm.202400149

[120]

He Y, Zan X, Miao J, Wang B, Wu Y, et al. 2022. Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles. Materials Today Bio 16:100423

doi: 10.1016/j.mtbio.2022.100423

[121]

Donati B, Lorenzini E, Ciarrocchi A. 2018. BRD4 and cancer: going beyond transcriptional regulation. Molecular Cancer 17:164

doi: 10.1186/s12943-018-0915-9

[122]

García Jiménez D, Rossi Sebastiano M, Vallaro M, Mileo V, Pizzirani D, et al. 2022. Designing soluble PROTACs: strategies and preliminary guidelines. Journal of Medicinal Chemistry 65:12639−12649

doi: 10.1021/acs.jmedchem.2c00201

[123]

Guo Y, You H, Li Y, Zhou Z, Tian Z, et al. 2025. Polymer-engineered PROTAC nanovehicles amplify synergistic effects with temozolomide by BRD4 degradation. Biomaterials Science 13:5001−5016

doi: 10.1039/d5bm00443h

[124]

Ruan C, Liu L, Lu Y, Zhang Y, He X, et al. 2018. Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma. Acta Pharmaceutica Sinica B 8:85−96

doi: 10.1016/j.apsb.2017.09.008

[125]

Yu W, Gong E, Wang C, Che C, Zhao Y, et al. 2024. In situ implantable DNA hydrogel for diagnosis and therapy of postoperative rehemorrhage following intracerebral hemorrhage surgery. Science Advances 10:eado3919

doi: 10.1126/sciadv.ado3919

[126]

Wang WD, Guo YY, Yang ZL, Su GL, Sun ZJ. 2023. Sniping cancer stem cells with nanomaterials. ACS Nano 17:23262−23298

doi: 10.1021/acsnano.3c07828

[127]

Gao Y, Shi W, Klawa SJ, Daly ML, Samulski ET, et al. 2025. Reversible metamorphosis of hierarchical DNA–inorganic crystals. Nature Nanotechnology 20:1813−1821

doi: 10.1038/s41565-025-02026-8

[128]

Kim MG, Park JY, Shim G, Choi HG, Oh YK. 2015. Biomimetic DNA nanoballs for oligonucleotide delivery. Biomaterials 62:155−163

doi: 10.1016/j.biomaterials.2015.04.037

[129]

Xu Q, Hu X, Ullah I, Lin T, Liu Y, et al. 2025. Biomimetic hybrid PROTAC nanovesicles block multiple DNA repair pathways to overcome temozolomide resistance against orthotopic glioblastoma. Advanced Materials 37:2504253

doi: 10.1002/adma.202504253

[130]

Erwin N, De U, Xiao Y, Wang L, Maharjan CK, et al. 2025. Proteolysis targeting chimera loaded extracellular vesicles for developing triple negative breast cancer treatment. Journal of Extracellular Vesicles 14:e70211

doi: 10.1002/jev2.70211

[131]

Silva RO, Haddad M, Counil H, Zaouter C, Patten SA, et al. 2025. Exploring the potential of plasma and adipose mesenchymal stem cell-derived extracellular vesicles as novel platforms for neuroinflammation therapy. Journal of Controlled Release 377:880−898

doi: 10.1016/j.jconrel.2024.11.060

[132]

Jin Y, Fan J, Wang R, Wang X, Li N, et al. 2023. Ligation to scavenging strategy enables on-demand termination of targeted protein degradation. Journal of the American Chemical Society 145:7218−7229

doi: 10.1021/jacs.2c12809

[133]

González-Gallego J, Todorov-Völgyi K, Müller SA, Antesberger S, Todorov MI, et al. 2026. A fully iPS-cell-derived 3D model of the human blood–brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions. Nature Neuroscience 29:479−492

doi: 10.1038/s41593-025-02123-w

[134]

Hoshi Y, Uchida Y, Tachikawa M, Inoue T, Ohtsuki S, et al. 2013. Quantitative atlas of blood–brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. Journal of Pharmaceutical Sciences 102:3343−3355

doi: 10.1002/jps.23575